Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

CT-388

ZYNERGY

Roche · Phase 2 · Not yet recruiting · Enrollment 486

NCT07589686

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Arm 1: Petrelintide + Enicepatide Dosing Regimen 1n/rn/rn/rn/r
Arm 2: Petrelintide + Enicepatide Dosing Regimen 2n/rn/rn/rn/r
Arm 3: Petrelintide + Enicepatide Dosing Regimen 3n/rn/rn/rn/r
Arm 4: Petrelintide-matching Placebo + Enicepatiden/rn/rn/rn/r
Arm 5: Petrelintide + Enicepatide-matching Placebon/rn/rn/rn/r
Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebon/rn/rn/rn/r

Not shown

  • Arm 1: Petrelintide + Enicepatide Dosing Regimen 1: endpoint not reported
  • Arm 2: Petrelintide + Enicepatide Dosing Regimen 2: endpoint not reported
  • Arm 3: Petrelintide + Enicepatide Dosing Regimen 3: endpoint not reported
  • Arm 4: Petrelintide-matching Placebo + Enicepatide: endpoint not reported
  • Arm 5: Petrelintide + Enicepatide-matching Placebo: endpoint not reported
  • Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebo: endpoint not reported